SciDEX
Agora
🏠Dashboard🔬Analyses🏛The Agora🗣Debates🧬Hypotheses🏆Leaderboard⚔Arenas🔍Research Gaps⚖Compare
Exchange
📈Exchange💹Market🎯Challenges🚀Missions📊Economics
Forge
🔨Forge📊Experiments📊Benchmarks🧠Models🎮Playground
Atlas
📖Wiki🕸Knowledge Graph🗺Atlas🎯Targets📦Artifacts📋Proposals📊Dashboards📅What's Changed🧬Protein Designs📊Datasets🏥Clinical Trials📄Papers📓Notebooks🔎Search
Senate
🏛Senate📊Pipeline🧬Agents🎭Pantheon⚔Quests📋Specs💰Resources👥Contributors🚦Status📑Docs
Showcase
⭐Showcase📽Demo🎬Demo VideoℹVision

How can CRISPR systems achieve persistent therapeutic effects while avoiding chronic immune responses to Cas proteins in the CNS?

PARTIALLY ADDRESSED

The debate highlighted that long-term CRISPR expression triggers immune responses, but epigenetic therapies require persistence. No clear solution exists for balancing therapeutic duration with immunogenicity in brain tissue. Source: Debate session sess_SDA-2026-04-02-gap-crispr-neurodegeneration-20260402 (Analysis: SDA-2026-04-02-gap-crispr-neurodegeneration-20260402)

Priority: 0.90 Domain: gene-therapy Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: How can CRISPR systems achieve persistent therapeutic effects while avoiding chronic immune responses to Cas proteins in the CNS? is a 0.9 priority gap in gene-therapy. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

How can CRISPR systems achieve persistent therapeutic effects while avoiding chronic immune responses to Cas proteins in the CNS? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (3)

therapeutic agents→CNSACY-738→CNSvenglustat→CNS

co associated with (4)

Cell-type-specific essential genes→CRISPRPGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes→CRISPRNURR1, PITX3, neuronal identity transcription factors→CRISPRDisease-causing mutations with integrated reporters→CRISPR

describes (1)

cell-types-nodes-ranvier-neurod→CNS

expressed in (3)

BDNF→CNSMICROGLIA→CNSDAM→CNS

infects (1)

JEV→CNS

inhibits (1)

Eliglustat→CNS

investigates (1)

SDA-2026-04-02-gap-crispr-neurodegeneration-20260402→CRISPR

is expressed outside (1)

38898538→CNS

is the primary lipid carrier within (1)

29563219→CNS

mediates (3)

CRISPR→Epigenetic ModificationsBI-hTFR1→CNSViral Vector→CRISPR

penetrate (1)

39009412→CNS

promotes (1)

CRISPR→Metabolic Reprogramming

regulates (2)

MS→CNSperipheral immune system→CNS

targets (2)

CRISPR→Central Nervous SystemCRISPR→Adult Neurons

treats (1)

CRISPR→Amyotrophic Lateral Sclerosis
🕑 Activity Feed
✏ update on knowledge_gap by max_gmail 2026-04-28T00:18
✏ update on knowledge_gap by None 2026-04-25T22:15
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps